501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro

The newly emerging variants of SARS-CoV-2 from South Africa (B.1.351/501Y.V2) and Brazil (P.1/501Y.V3) have led to a higher infection rate and reinfection of COVID-19 patients. We found that the mutations K417N, E484K, and N501Y within the receptor-binding domains (RBDs) of the virus could confer ~2...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Haolin Liu, Pengcheng Wei, Qianqian Zhang, Zhongzhou Chen, Katja Aviszus, Walter Downing, Shelley Peterson, Lyndon Reynoso, Gregory P. Downey, Stephen K. Frankel, John Kappler, Philippa Marrack, Gongyi Zhang
Формат: Artigo
Язык:Inglês
Опубликовано: Taylor & Francis Group 2021-01-01
Серии:mAbs
Предметы:
SARS-COV-2
COVID-19
B.1.1.7/501Y.V1
B.1.351/501Y.V2
P.1/501Y.V3
ACE2
Online-ссылка:https://www.tandfonline.com/doi/10.1080/19420862.2021.1919285
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы